logo
Superfeet Readies Carbon-Plated Insoles For Running And Cleated Sports

Superfeet Readies Carbon-Plated Insoles For Running And Cleated Sports

Forbes06-06-2025
Superfeet will debut the Run Pacer Elite fully carbon fiber insole plate for running in October.
As Superfeet nears 50 years making insoles, the Pacific Northwest brand did more than redesign a logo and packaging. Superfeet now readies a fresh approach to carbon fiber that can help turn the most comfortable and durable running shoe into carbon fiber-plated footwear. And that's just the start, with plans for a carbon-fiber model for cleated footwear coming next.
'Back in 2013 we pioneered the use of a hybrid polymer of plastic and carbon fiber blended together,' Matt Gooch, Superfeet vice president of product and innovation, tells me. 'Since that time, we have utilized it a lot in our product line, but we have never had a full 100% carbon fiber component.'
That changes in October with the launch of the Run Pacer Elite insole, a full-length carbon fiber plate created in partnership with Carbitex that includes layers of super critical foam. Gooch says the carbon allows for incredible flexibility in one direction and then extreme stiffness in the other that changes based on the amount of pressure placed on the product.
At slower speeds, the insole offers dynamic stability in the propulsive phase and as forces get higher—as speeds get faster—the unique properties allow the plate to engage sooner and get stiffer for a longer portion of the gate cycle. Basically, the harder you work the carbon fiber, the longer it provides propulsive benefits, Gooch says.
Superfeet has nearly 50 years of insole history.
Superfeet has paired the carbon fiber with the brand's SuperRev high energy return foam, with layers of foam beads and a foam bed. The combination gives runners improvement in stability, up to 40% better forefoot stability based on testing, Gooch says. The foam also allows the insole to retain the classic Superfeet shape and provide a responsive feel longer in the motion.
Gooch says that a carbon fiber insole gives runners more flexibility in their training. It can allow them to add the insole to a training shoe that might fit them better, be more comfortable and more durable, still dialing up high-performance experiences. For someone with a shoe rotation, Gooch says they can tune that experience further with a carbon fiber insole by making long runs feel snappier or adding pop to a tempo or workout shoe. For someone who a carbon-plated shoe isn't an option, adding the insole will provide the benefits longer because the insole can be moved from shoe to shoe.
'We are trying to create this space where more people can hybridize and control the experience they want from their footwear when training,' Gooch says. 'This empowers them to stay moving and stay training.'
As more running shoes enter the market with carbon fiber part of the equation, Gooch says getting the technology as close to the foot provides the most benefit. An insole is as close as you can get and with a plate that isn't at a set curvature, offers more personalization than many other products.
Superfeet will debut a new Sport Ultralight lineup of insoles in early fall.
'What is unique is the combination of the things we are putting together,' Gooch says. 'The combination of materials and the build that we have with the Carbitex plate delvers something very interesting and unique.'
One challenge was creating a product that wasn't duplicative of the brand's already large portfolio of running insoles. Gooch says they worked to amplify performance while refining the brand's position in the space. 'This doesn't feel or perform like any other product,' he says. 'It still has the Superfeet shape, it is incredibly durable and we deliver on those expectations, but it is going to feel different. I think that is something we are really excited about.'
The Run Pacer Elite has a running-specifc design with contours through the arch, a cut-away for heel strike and a design that allows the big toe to do the heavy lifting of stability.
With such a focus on running for the first carbon fiber product, the Cleat Insole adds to the lineup in early 2026. And it looks quite different. Designed with sports such as soccer in mind, Superfeet took a minimalist approach because of the style of footwear. The carbon fiber plate had to accommodate the pivot points and flexibility needed in the foot while still allowing the wear contact with the individual cleats. It made for a completely unique plate design.
'There are probably a lot of people who could benefit from these insoles who never thought of wearing insoles in the past,' Gooch says. 'We had to think: 'How do we give them a really compelling reason?''
The Cleat Insole is narrow to fit inside cleats, has a cutout on the heel to not add heel height, doesn't feature a uniform stiffness—as the angle increases it gets progressively stiffer—to fit with the needs of cleated sports and has overlays in high friction areas to keep the foot connected. The insole also features SuperRev foam.
As Superfeet starts exploring the fully carbon, specifically sport world of insoles, Gooch says the Run Pacer Elite will serve as the jumping off point. 'We are really excited,' he says, 'about our continued evolution of what Superfeet has been doing. We can take the footwear you already trust and find ways to amplify the performance in ways that haven't been available from an insole.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Why Google should 'walk away' from Waymo
Why Google should 'walk away' from Waymo

Yahoo

time14 minutes ago

  • Yahoo

Why Google should 'walk away' from Waymo

Needham & Company senior media and internet analyst Laura Martin joins Market Domination with Josh Lipton to explain why Alphabet (GOOG, GOOGL) should ditch Waymo and focus on generative artificial intelligence (AI) instead. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. Related videos The £70bn pension tax raid Reeves may not be able to resist 10 shares I wouldn't want to hold in a stock market crash After falling 16% in a day, this stock's on my list of shares to buy in August This FTSE 250 trust is easily beating the global index in 2025. Time to buy? Sign in to access your portfolio

EMCOR Group (EME) Sees EPS Surge as Net Income Climbs to US$241 Million
EMCOR Group (EME) Sees EPS Surge as Net Income Climbs to US$241 Million

Yahoo

time14 minutes ago

  • Yahoo

EMCOR Group (EME) Sees EPS Surge as Net Income Climbs to US$241 Million

EMCOR Group recently announced a regular quarterly cash dividend of $0.25 per common share, to be paid on July 31, 2025. This steady dividend approach aligns with the company's robust quarterly performance, which saw net income rise to $241 million and EPS increase substantially year-over-year. Additionally, the ongoing share buyback program has strengthened shareholder returns. Despite the broader market's moderate growth of 1.4% over the past week and 17% over the past year, EMCOR's notable share repurchases and solid financial outcomes appear to have amplified investor confidence, contributing to the company's impressive 55% stock price surge last quarter. We've spotted 1 risk for EMCOR Group you should be aware of. Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit. EMCOR Group's recent announcement of a quarterly dividend and the implementation of its share buyback program underline its commitment to enhancing shareholder returns. Despite a potential downside to the current share price of US$635.06, which exceeds the consensus analyst price target of US$549.57 by 13.46%, these actions could continue to buoy investor confidence. The company's performance over the past five years, with a total return exceeding 844.60%, showcases its robust long-term trajectory. In the last year, EMCOR's share performance exceeded both the broader market's 17.2% and the US Construction industry's 54.2% return, highlighting its strong standing relative to peers. The successful integration of acquisitions and strategic diversification into sectors like data centers and healthcare is anticipated to impact future revenue positively. This, coupled with operational efficiencies and strong revenue collaboration, may reinforce earnings projections. However, EMCOR's earnings forecasts of a 6.2% annual growth rate lag behind the broader market's 14.9% forecast, which could present challenges in meeting broader industry expectations. The company's impressive share price rise of 55% last quarter signals optimism, though its current value being above the target may indicate overvaluation concerns. Nevertheless, the consistent cash flow and healthy margins underscore its potential resilience against margin pressures, supply chain challenges, and other economic uncertainties. As analysts estimate revenue growth to 7.9% annually over the next three years, any tangible improvement in operational metrics could shift the valuation outlook positively. Unlock comprehensive insights into our analysis of EMCOR Group stock in this financial health report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include EME. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Pfizer (PFE) Receives CHMP Recommendation For Adapted COVID-19 Vaccine COMIRNATY
Pfizer (PFE) Receives CHMP Recommendation For Adapted COVID-19 Vaccine COMIRNATY

Yahoo

time14 minutes ago

  • Yahoo

Pfizer (PFE) Receives CHMP Recommendation For Adapted COVID-19 Vaccine COMIRNATY

BioNTech SE and Pfizer recently received a positive recommendation from the European Medicines Agency for marketing authorization of their COVID-19 vaccine, which likely contributed to Pfizer's share price increase of 8% in the last quarter. The company's advancements in COVID-19 vaccine development, alongside other product-related announcements like the XTANDI and BRAFTOVI trial results, added weight to this upward movement. Despite legal challenges and declining earnings, Pfizer's focus on innovation and strategic partnerships like the one with XtalPi possibly countered broader market moves, which saw a smaller 1% increase in the same period. We've identified 3 warning signs for Pfizer that you should be aware of. Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave. The recent positive recommendation from the European Medicines Agency for the COVID-19 vaccine developed by BioNTech SE and Pfizer has contributed to an 8% increase in Pfizer's share price over the last quarter. This news may provide a temporary boost to Pfizer's revenue and earnings forecasts, especially as the company continues to innovate amidst legal challenges and declining earnings. The authorization could enhance immediate market confidence in Pfizer's product pipeline, impacting future revenue projections positively. Over the past year, Pfizer experienced a total return of 13.78% including dividends, reflecting a challenging period for shareholders. When compared to the broader US market's return of 17.2% over the same period, Pfizer has underperformed, highlighting investor concerns over competitive pressures and revenue growth prospects. The current share price movement toward the analyst consensus price target of $29.23 suggests a cautiously optimistic outlook among some market participants. Analysts' revenue forecasts reflect potential declines due to increased competition for existing products, yet others anticipate that strategic shifts in research focus, especially in oncology, might mitigate future earnings risks. With a modest increase of 8% in shares largely tied to vaccine authorization, it underscores the uncertainty surrounding longer-term performance relative to bearish analyst expectations. Understand Pfizer's track record by examining our performance history report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include PFE. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store